Interleukin-35 in Immune-related Diseases: Protection or Destruction

Overview

Journal Immunology

Specialty Allergy & Immunology

Date 2019 Jan 26

PMID 30681737

Citations 35

Authors

Junfeng Zhang

Yunsheng Zhang

Qingpeng Wang

Chunlei Li

Hongxin Deng

Chuanping Si

Huabao Xiong

Affiliations

Soon will be listed here.

Abstract

Interleukin-35 (IL-35) is a recently identified heterodimeric cytokine in the IL-12 family. It consists of an IL-12 subunit α chain (P35) and IL-27 subunit Epstein-Barr virus-induced gene 3 (EBI3) β chain. Unlike the other IL-12 family members, it signals through four unconventional receptors: IL-12Rβ2-IL-27Rα, IL-12Rβ2-IL-12Rβ2, IL-12Rβ2-GP130, and GP130-GP130. Interleukin-35 signaling is mainly carried out through the signal transducer and activator of transcription family of proteins. It is secreted not only by regulatory T (Treg) cells, but also by CD8 Treg cells, activated dendritic cells and regulatory B cells. It exhibits immunosuppressive functions distinct from those of other members of the IL-12 family; these are mediated primarily by the inhibition of T helper type 17 cell differentiation and promotion of Treg cell proliferation. Interleukin-35 plays a critical role in several immune-associated diseases, such as autoimmune diseases and viral and bacterial infections, as well as in tumors. In this review, we summarize the structure and function of IL-35, describe its role in immune-related disorders, and discuss the mechanisms by which it regulates the development and progression of diseases, including inflammatory bowel disease, collagen-induced arthritis, allergic airway disease, hepatitis, and tumors. The recent research on IL-35, combined with improved techniques of studying receptors and signal transduction pathways, allows for consideration of IL-35 as a novel immunotherapy target.

Citing Articles

The role of chemokines and interleukins in acute lymphoblastic leukemia: a systematic review.

Stajer M, Horacek J, Kupsa T, Zak P J Appl Biomed. 2025; 22(4):165-184.

PMID: 40033805 DOI: 10.32725/jab.2024.024.

The effects of compound probiotics on production performance, rumen fermentation and microbiota of sheep.

Wang L, Lv Z, Ning X, Yue Z, Wang P, Liu C Front Vet Sci. 2024; 11:1440432.

PMID: 39545259 PMC: 11560882. DOI: 10.3389/fvets.2024.1440432.

Interleukin-35: A key player managing pre-diabetes and chronic inflammatory type 1 autoimmune diabetes.

Chakraborty R, Mukherjee A, Bala A World J Diabetes. 2024; 15(10):2147-2151.

PMID: 39493554 PMC: 11525726. DOI: 10.4239/wjd.v15.i10.2147.

Serum Levels of IL-35, One of the Newest Members of Interleukin-12 Family of Cytokines, in Patients With Vitiligo.

Hayran Y, Yucel C, Firat Oguz E, Eren F, Turhan T, Yalcin B Dermatol Pract Concept. 2024; 14(2).

PMID: 38810045 PMC: 11135918. DOI: 10.5826/dpc.1402a69.

Regulation of Treg cells by cytokine signaling and co-stimulatory molecules.

Zong Y, Deng K, Chong W Front Immunol. 2024; 15:1387975.

PMID: 38807592 PMC: 11131382. DOI: 10.3389/fimmu.2024.1387975.

References

Courtenay J, Dallman M, Dayan A, Martin A, Mosedale B . Immunisation against heterologous type II collagen induces arthritis in mice. Nature. 1980; 283(5748):666-8. DOI: 10.1038/283666a0. View

Kochetkova I, Thornburg T, Callis G, Pascual D . Segregated regulatory CD39+CD4+ T cell function: TGF-β-producing Foxp3- and IL-10-producing Foxp3+ cells are interdependent for protection against collagen-induced arthritis. J Immunol. 2011; 187(9):4654-66. PMC: 3237119. DOI: 10.4049/jimmunol.1100530. View

Banchereau J, Pascual V, OGarra A . From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol. 2012; 13(10):925-31. PMC: 3609707. DOI: 10.1038/ni.2406. View

Devergne O, Birkenbach M, Kieff E . Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci U S A. 1997; 94(22):12041-6. PMC: 23696. DOI: 10.1073/pnas.94.22.12041. View

Kastelein R, Hunter C, Cua D . Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol. 2007; 25:221-42. DOI: 10.1146/annurev.immunol.22.012703.104758. View

Pflanz S, Timans J, Cheung J, Rosales R, Kanzler H, Gilbert J . IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity. 2002; 16(6):779-90. DOI: 10.1016/s1074-7613(02)00324-2. View

Collison L, Pillai M, Chaturvedi V, Vignali D . Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J Immunol. 2009; 182(10):6121-8. PMC: 2698997. DOI: 10.4049/jimmunol.0803646. View

Mikus L, Rosenthal L, Sorkness R, Lemanske Jr R . Reduced interferon-gamma secretion by natural killer cells from rats susceptible to postviral chronic airway dysfunction. Am J Respir Cell Mol Biol. 2001; 24(1):74-82. DOI: 10.1165/ajrcmb.24.1.4125. View

Jiang S, Li Y, Lin T, Yuan L, Li Y, Wu S . IL-35 Inhibits Angiogenesis through VEGF/Ang2/Tie2 Pathway in Rheumatoid Arthritis. Cell Physiol Biochem. 2016; 40(5):1105-1116. DOI: 10.1159/000453165. View

10.

Yoshio S, Kanto T . [Immunopathogenesis of hepatitis B virus infection]. Nihon Rinsho. 2016; 73 Suppl 9:361-5. View

11.

Yang J, Yang M, Htut T, Ouyang X, Hanidu A, Li X . Epstein-Barr virus-induced gene 3 negatively regulates IL-17, IL-22 and RORgamma t. Eur J Immunol. 2008; 38(5):1204-14. PMC: 2989250. DOI: 10.1002/eji.200838145. View

12.

Collison L, Vignali D . Interleukin-35: odd one out or part of the family?. Immunol Rev. 2009; 226:248-62. PMC: 2631363. DOI: 10.1111/j.1600-065X.2008.00704.x. View

13.

Nicholl M, Ledgewood C, Chen X, Bai Q, Qin C, Cook K . IL-35 promotes pancreas cancer growth through enhancement of proliferation and inhibition of apoptosis: evidence for a role as an autocrine growth factor. Cytokine. 2014; 70(2):126-33. DOI: 10.1016/j.cyto.2014.06.020. View

14.

Manzoor F, Johnson M, Li C, Samulski R, Wang B, Tisch R . β-cell-specific IL-35 therapy suppresses ongoing autoimmune diabetes in NOD mice. Eur J Immunol. 2016; 47(1):144-154. PMC: 5233468. DOI: 10.1002/eji.201646493. View

15.

Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R . Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med. 2004; 199(11):1567-75. PMC: 2211782. DOI: 10.1084/jem.20032058. View

16.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

17.

Li X, Fang P, Yang W, Wang H, Yang X . IL-35, as a newly proposed homeostasis-associated molecular pattern, plays three major functions including anti-inflammatory initiator, effector, and blocker in cardiovascular diseases. Cytokine. 2017; 122:154076. PMC: 5741534. DOI: 10.1016/j.cyto.2017.06.003. View

18.

Bettini M, Castellaw A, Lennon G, Burton A, Vignali D . Prevention of autoimmune diabetes by ectopic pancreatic β-cell expression of interleukin-35. Diabetes. 2012; 61(6):1519-26. PMC: 3357277. DOI: 10.2337/db11-0784. View

19.

Turnis M, Sawant D, Szymczak-Workman A, Andrews L, Delgoffe G, Yano H . Interleukin-35 Limits Anti-Tumor Immunity. Immunity. 2016; 44(2):316-29. PMC: 4758699. DOI: 10.1016/j.immuni.2016.01.013. View

20.

Yang X, Panopoulos A, Nurieva R, Chang S, Wang D, Watowich S . STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem. 2007; 282(13):9358-9363. DOI: 10.1074/jbc.C600321200. View